In the current study, we utilized the Bcl-2 inhibitor, HA14-1, to mimic loss of Bcl-2 function and assess the neuroprotective potential of Immunocal
Even so, moving from this biochemical function to clinical outcomes is not always straightforward: the evidence can be heterogeneous and depends on dose, duration, the population studied and lifestyle variables
doi: 10.1038/s41590-018-0287-8 126 SugimotoA.MaedaA.IttoK.ArimotoH
Researchers were looking for free glutathione levels, and because glutathione is so valuable, it is quickly bound to transport proteins to be carried to cells, causing it to not show up as free glutathione in the blood
the combined formulation has not been formally trialed
Market changes and negotiated pricing programs may help bridge the gap